Document is current
Any future updates will be listed below
-
Authors
Fischer, David S. https://orcid.org/0000-0002-1293-7656
Ansari, Meshal https://orcid.org/0000-0002-8819-7965
Wagner, Karolin I. https://orcid.org/0000-0001-8418-983X
Jarosch, Sebastian https://orcid.org/0000-0002-2908-8590
Huang, Yiqi https://orcid.org/0000-0001-7256-8699
Mayr, Christoph H.
Strunz, Maximilian
Lang, Niklas J.
D’Ippolito, Elvira https://orcid.org/0000-0003-0113-6797
Hammel, Monika
Mateyka, Laura
Weber, Simone https://orcid.org/0000-0001-5280-2142
Wolff, Lisa S.
Witter, Klaus
Fernandez, Isis E.
Leuschner, Gabriela
Milger, Katrin
Frankenberger, Marion
Nowak, Lorenz
Heinig-Menhard, Katharina
Koch, Ina
Stoleriu, Mircea G.
Hilgendorff, Anne https://orcid.org/0000-0002-3725-996X
Behr, Jürgen
Pichlmair, Andreas https://orcid.org/0000-0002-0166-1367
Schubert, Benjamin
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
Busch, Dirk H. https://orcid.org/0000-0001-8713-093X
Schiller, Herbert B. https://orcid.org/0000-0001-9498-7034
Schober, Kilian https://orcid.org/0000-0001-9323-9472
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KX2021, 01IS18036B, 01IS18053A))
Deutsche Forschungsgemeinschaft (SFB1321/TP17, SFB1054/B09, SFB1371/TP04)
Deutsche Zentrum für Lungenforschung
Helmholtz Association (ZT-I-PF-5-01)
EC | Horizon 2020 Framework Programme (874656)
- License Information
-
More Information
Article History
Received: 18 December 2020
Accepted: 16 June 2021
First Online: 26 July 2021
Competing interests
: D.H.B. is co-founder of STAGE Cell Therapeutics GmbH (now Juno Therapeutics/BMS) and T Cell Factory B.V. (now Kite/Gilead). D.H.B. has a consulting contract with and receives sponsored research support from Juno Therapeutics/BMS. F.J.T. reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and an ownership interest in Cellarity, Inc., and Dermagnostix. The remaining authors declare no competing interests.
